Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1347 entries
Sorted by: Best Match Show Resources per page
Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy.

Annals of medical and health sciences research

Madu A, Ocheni S, Ibegbulam O, Aguwa E, Madu K.
PMID: 24379998
Ann Med Health Sci Res. 2013 Oct;3(4):498-503. doi: 10.4103/2141-9248.122054.

BACKGROUND: Assessment of patients prior to cytotoxic chemotherapy usually includes absolute neutrophils count. Other cellular markers of susceptibility to infection as well as immunocompetence include the T Helper lymphocyte count. In cancer patients, decrease in these lymphocytes has been...

Cite
Madu A, Ocheni S, Ibegbulam O, et al. Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy. Ann Med Health Sci Res. 2013;3(4):498-503doi: 10.4103/2141-9248.122054.
Madu, A., Ocheni, S., Ibegbulam, O., Aguwa, E., & Madu, K. (2013). Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy. Annals of medical and health sciences research, 3(4), 498-503. https://doi.org/10.4103/2141-9248.122054
Madu, Aj, et al. "Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy." Annals of medical and health sciences research vol. 3,4 (2013): 498-503. doi: https://doi.org/10.4103/2141-9248.122054
Madu A, Ocheni S, Ibegbulam O, Aguwa E, Madu K. Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy. Ann Med Health Sci Res. 2013 Oct;3(4):498-503. doi: 10.4103/2141-9248.122054. PMID: 24379998; PMCID: PMC3868113.
Copy Download .nbib Format: NLM
Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy.

Case reports in oncological medicine

Mohtaram A, Afif M, Sghiri T, Rami A, Latib R, Kettani F, Ben Ameur El Youbi M, Boutayeb S, Kebdani T, Benjaafar N, Aaribi I, Errihani H.
PMID: 24381772
Case Rep Oncol Med. 2013;2013:487205. doi: 10.1155/2013/487205. Epub 2013 Dec 05.

Background. Castleman's disease is a rare clinicopathological entity of unknown origin. Coexistence of Hodgkin's lymphoma and Castleman's disease is rare. We report a case of Hodgkin's disease of cervical lymph nodes in a patient previously diagnosed with Castleman's disease....

Cite
Mohtaram A, Afif M, Sghiri T, et al. Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Case Rep Oncol Med. 2013;2013:487205doi: 10.1155/2013/487205.
Mohtaram, A., Afif, M., Sghiri, T., Rami, A., Latib, R., Kettani, F., Ben Ameur El Youbi, M., Boutayeb, S., Kebdani, T., Benjaafar, N., Aaribi, I., & Errihani, H. (2013). Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Case reports in oncological medicine, 2013487205. https://doi.org/10.1155/2013/487205
Mohtaram, Amina, et al. "Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy." Case reports in oncological medicine vol. 2013 (2013): 487205. doi: https://doi.org/10.1155/2013/487205
Mohtaram A, Afif M, Sghiri T, Rami A, Latib R, Kettani F, Ben Ameur El Youbi M, Boutayeb S, Kebdani T, Benjaafar N, Aaribi I, Errihani H. Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Case Rep Oncol Med. 2013;2013:487205. doi: 10.1155/2013/487205. Epub 2013 Dec 05. PMID: 24381772; PMCID: PMC3870129.
Copy Download .nbib Format: NLM
Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation.

Radiology and oncology

Girelli R, Prejanò S, Cataldo I, Corbo V, Martini L, Scarpa A, Claudio B.
PMID: 26029026
Radiol Oncol. 2015 Mar 25;49(2):147-54. doi: 10.1515/raon-2015-0013. eCollection 2015 Jun.

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease generally refractory to standard chemotherapeutic agents; therefore improvements in anticancer therapies are mandatory. A major determinant of therapeutic resistance in PDAC is the poor drug delivery to neoplastic cells, mainly...

Cite
Girelli R, Prejanò S, Cataldo I, et al. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol. 2015;49(2):147-54doi: 10.1515/raon-2015-0013.
Girelli, R., Prejanò, S., Cataldo, I., Corbo, V., Martini, L., Scarpa, A., & Claudio, B. (2015). Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiology and oncology, 49(2), 147-54. https://doi.org/10.1515/raon-2015-0013
Girelli, Roberto, et al. "Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation." Radiology and oncology vol. 49,2 (2015): 147-54. doi: https://doi.org/10.1515/raon-2015-0013
Girelli R, Prejanò S, Cataldo I, Corbo V, Martini L, Scarpa A, Claudio B. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol. 2015 Mar 25;49(2):147-54. doi: 10.1515/raon-2015-0013. eCollection 2015 Jun. PMID: 26029026; PMCID: PMC4387991.
Copy Download .nbib Format: NLM
MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1.

American journal of translational research

Zhuang Y, Dai J, Wang Y, Zhang H, Li X, Wang C, Cao M, Liu Y, Cai H, Zhang D, Wang Y.
PMID: 27508041
Am J Transl Res. 2016 Jul 15;8(7):3197-205. eCollection 2016.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease involving pulmonary injury associated with tissue repair, dysfunction and fibrosis. MicroRNAs (miRNAs), as gene regulators, are assumed to regulate about one third of genes and thus play important roles in...

Cite
Zhuang Y, Dai J, Wang Y, et al. MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1. Am J Transl Res. 2016;8(7):3197-205
Zhuang, Y., Dai, J., Wang, Y., Zhang, H., Li, X., Wang, C., Cao, M., Liu, Y., Cai, H., Zhang, D., & Wang, Y. (2016). MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1. American journal of translational research, 8(7), 3197-205.
Zhuang, Yi, et al. "MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1." American journal of translational research vol. 8,7 (2016): 3197-205.
Zhuang Y, Dai J, Wang Y, Zhang H, Li X, Wang C, Cao M, Liu Y, Cai H, Zhang D, Wang Y. MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1. Am J Transl Res. 2016 Jul 15;8(7):3197-205. eCollection 2016. PMID: 27508041; PMCID: PMC4969457.
Copy Download .nbib Format: NLM
MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition.

American journal of translational research

Zhuang Y, Dai J, Wang Y, Zhang H, Li X, Wang C, Cao M, Liu Y, Ding J, Cai H, Zhang D, Wang Y.
PMID: 27508042
Am J Transl Res. 2016 Jul 15;8(7):3206-13. eCollection 2016.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease involving pulmonary injury associated with tissue repair, dysfunction and fibrosis. Recent studies indicate that some microRNAs (miRNAs) may play critical roles in the pathogenesis of pulmonary fibrosis. In this study,...

Cite
Zhuang Y, Dai J, Wang Y, et al. MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition. Am J Transl Res. 2016;8(7):3206-13
Zhuang, Y., Dai, J., Wang, Y., Zhang, H., Li, X., Wang, C., Cao, M., Liu, Y., Ding, J., Cai, H., Zhang, D., & Wang, Y. (2016). MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition. American journal of translational research, 8(7), 3206-13.
Zhuang, Yi, et al. "MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition." American journal of translational research vol. 8,7 (2016): 3206-13.
Zhuang Y, Dai J, Wang Y, Zhang H, Li X, Wang C, Cao M, Liu Y, Ding J, Cai H, Zhang D, Wang Y. MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition. Am J Transl Res. 2016 Jul 15;8(7):3206-13. eCollection 2016. PMID: 27508042; PMCID: PMC4969458.
Copy Download .nbib Format: NLM
Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors.

Radiology and oncology

Dolinsek T, Prosen L, Cemazar M, Potocnik T, Sersa G.
PMID: 27679543
Radiol Oncol. 2016 Jul 19;50(3):274-9. doi: 10.1515/raon-2016-0042. eCollection 2016 Sep 01.

BACKGROUND: The aim of the study was to explore the effectiveness of electrochemotherapy (ECT) during the treatment of melanoma patients with BRAF inhibitors. Its effectiveness was tested on BRAF mutated and non-mutated melanoma cells in vitro and in combination...

Cite
Dolinsek T, Prosen L, Cemazar M, et al. Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiol Oncol. 2016;50(3):274-9doi: 10.1515/raon-2016-0042.
Dolinsek, T., Prosen, L., Cemazar, M., Potocnik, T., & Sersa, G. (2016). Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiology and oncology, 50(3), 274-9. https://doi.org/10.1515/raon-2016-0042
Dolinsek, Tanja, et al. "Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors." Radiology and oncology vol. 50,3 (2016): 274-9. doi: https://doi.org/10.1515/raon-2016-0042
Dolinsek T, Prosen L, Cemazar M, Potocnik T, Sersa G. Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiol Oncol. 2016 Jul 19;50(3):274-9. doi: 10.1515/raon-2016-0042. eCollection 2016 Sep 01. PMID: 27679543; PMCID: PMC5024665.
Copy Download .nbib Format: NLM
Oncological Outcomes in Japanese Men Undergoing Orchiectomy for Stage I Testicular Germ Cell Tumor.

Current urology

Harada K, Miyake H, Ogawa T, Inoue TA, Fujisawa M.
PMID: 26889123
Curr Urol. 2015 Jul;8(2):84-90. doi: 10.1159/000365695. Epub 2015 Jul 10.

BACKGROUND: The objective of this study was to retrospectively review oncological outcomes in patients with stage I testicular germ cell tumor (GCT).PATIENTS AND METHODS: This study included 265 consecutive Japanese men undergoing orchiectomy for stage I testicular GCT, and...

Cite
Harada K, Miyake H, Ogawa T, et al. Oncological Outcomes in Japanese Men Undergoing Orchiectomy for Stage I Testicular Germ Cell Tumor. Curr Urol. 2015;8(2):84-90doi: 10.1159/000365695.
Harada, K., Miyake, H., Ogawa, T., Inoue, T. A., & Fujisawa, M. (2015). Oncological Outcomes in Japanese Men Undergoing Orchiectomy for Stage I Testicular Germ Cell Tumor. Current urology, 8(2), 84-90. https://doi.org/10.1159/000365695
Harada, Ken-Ichi, et al. "Oncological Outcomes in Japanese Men Undergoing Orchiectomy for Stage I Testicular Germ Cell Tumor." Current urology vol. 8,2 (2015): 84-90. doi: https://doi.org/10.1159/000365695
Harada K, Miyake H, Ogawa T, Inoue TA, Fujisawa M. Oncological Outcomes in Japanese Men Undergoing Orchiectomy for Stage I Testicular Germ Cell Tumor. Curr Urol. 2015 Jul;8(2):84-90. doi: 10.1159/000365695. Epub 2015 Jul 10. PMID: 26889123; PMCID: PMC4748785.
Copy Download .nbib Format: NLM
Relationship between head and neck cancer therapy and some genetic endpoints.

World journal of clinical oncology

Minicucci EM, da Silva GN, Salvadori DM.
PMID: 24829856
World J Clin Oncol. 2014 May 10;5(2):93-102. doi: 10.5306/wjco.v5.i2.93.

Head and neck cancer (HNC) is the sixth most common human malignancy worldwide. The main forms of treatment for HNC are surgery, radiotherapy (RT) and chemotherapy (CT). However, the choice of therapy depends on the tumor staging and approaches,...

Cite
Minicucci EM, da Silva GN, Salvadori DM. Relationship between head and neck cancer therapy and some genetic endpoints. World J Clin Oncol. 2014;5(2):93-102doi: 10.5306/wjco.v5.i2.93.
Minicucci, E. M., da Silva, G. N., & Salvadori, D. M. (2014). Relationship between head and neck cancer therapy and some genetic endpoints. World journal of clinical oncology, 5(2), 93-102. https://doi.org/10.5306/wjco.v5.i2.93
Minicucci, Eliana Maria, et al. "Relationship between head and neck cancer therapy and some genetic endpoints." World journal of clinical oncology vol. 5,2 (2014): 93-102. doi: https://doi.org/10.5306/wjco.v5.i2.93
Minicucci EM, da Silva GN, Salvadori DM. Relationship between head and neck cancer therapy and some genetic endpoints. World J Clin Oncol. 2014 May 10;5(2):93-102. doi: 10.5306/wjco.v5.i2.93. PMID: 24829856; PMCID: PMC4014801.
Copy Download .nbib Format: NLM
Electrochemotherapy: an emerging drug delivery method for the treatment of cancer.

Advanced drug delivery reviews

Heller R, Gilbert R, Jaroszeski MJ.
PMID: 10837542
Adv Drug Deliv Rev. 1997 Jul 07;26(2):185-197. doi: 10.1016/s0169-409x(97)00034-3.

The combined treatment consisting of a chemotherapeutic agent and pulsed electric fields has been termed electrochemotherapy. This relatively new treatment modality relies on the physical effects of locally applied electric fields to destabilize cell membranes in the presence of...

Cite
Heller R, Gilbert R, Jaroszeski MJ. Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. Adv Drug Deliv Rev. 1997;26(2):185-197doi: 10.1016/s0169-409x(97)00034-3.
Heller, R., Gilbert, R., & Jaroszeski, M. J. (1997). Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. Advanced drug delivery reviews, 26(2), 185-197. https://doi.org/10.1016/s0169-409x(97)00034-3
Heller, et al. "Electrochemotherapy: an emerging drug delivery method for the treatment of cancer." Advanced drug delivery reviews vol. 26,2 (1997): 185-197. doi: https://doi.org/10.1016/s0169-409x(97)00034-3
Heller R, Gilbert R, Jaroszeski MJ. Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. Adv Drug Deliv Rev. 1997 Jul 07;26(2):185-197. doi: 10.1016/s0169-409x(97)00034-3. PMID: 10837542.
Copy Download .nbib Format: NLM
Chemotherapy rapidly alternating with accelerated radiotherapy for advanced carcinoma of the uterine cervix.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Chadha M, Jacobs AJ, Stenson R.
PMID: 11578486
Int J Gynecol Cancer. 1995 Jul;5(4):257-261. doi: 10.1046/j.1525-1438.1995.05040257.x.

The objective of this study was to determine the feasibility of treating patients with advanced cervical carcinoma using a regimen combining chemotherapy with intermittent hyperfractionated teletherapy. Eight patients with advanced cervical carcinoma were treated with bleomycin, ifosfamide and cisplatin,...

Cite
Chadha M, Jacobs AJ, Stenson R. Chemotherapy rapidly alternating with accelerated radiotherapy for advanced carcinoma of the uterine cervix. Int J Gynecol Cancer. 1995;5(4):257-261doi: 10.1046/j.1525-1438.1995.05040257.x.
Chadha, M., Jacobs, A. J., & Stenson, R. (1995). Chemotherapy rapidly alternating with accelerated radiotherapy for advanced carcinoma of the uterine cervix. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 5(4), 257-261. https://doi.org/10.1046/j.1525-1438.1995.05040257.x
Chadha, M., et al. "Chemotherapy rapidly alternating with accelerated radiotherapy for advanced carcinoma of the uterine cervix." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 5,4 (1995): 257-261. doi: https://doi.org/10.1046/j.1525-1438.1995.05040257.x
Chadha M, Jacobs AJ, Stenson R. Chemotherapy rapidly alternating with accelerated radiotherapy for advanced carcinoma of the uterine cervix. Int J Gynecol Cancer. 1995 Jul;5(4):257-261. doi: 10.1046/j.1525-1438.1995.05040257.x. PMID: 11578486.
Copy Download .nbib Format: NLM
Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.

Seminars in radiation oncology

Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M.
PMID: 10717177
Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185.

Recommendations for the treatment of "poor prognosis" stages I and II Hodgkin's disease (HD) depend on the extent of staging. For centers that favor exploratory laparotomy and splenectomy, the standard treatment after negative surgical staging remains subtotal lymphoid irradiation....

Cite
Cosset JM, Fermé C, Noordijk EM, et al. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996;6(3):185-195doi: 10.1053/SRAO00600185.
Cosset, J. M., Fermé, C., Noordijk, E. M., Dubray, B. M., Thirion, P., & Henry-Amar, M. (1996). Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Seminars in radiation oncology, 6(3), 185-195. https://doi.org/10.1053/SRAO00600185
Cosset, et al. "Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease." Seminars in radiation oncology vol. 6,3 (1996): 185-195. doi: https://doi.org/10.1053/SRAO00600185
Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185. PMID: 10717177.
Copy Download .nbib Format: NLM
Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Vermorken JB, Mangioni C, Pecorelli S, Van Der Burg ME, Van Oosterom AT, Ten Bokkel Huinink WW, Rotmensz N, Dalesio O.
PMID: 11240699
Int J Gynecol Cancer. 2000 Sep;10(5):358-365. doi: 10.1046/j.1525-1438.2000.010005358.x.

The objective of this study was to study the antitumor activity of the vincristine, bleomycin, mitomycin C and cisplatin (VBMP) scheme in patients with disseminated squamous cell carcinoma of the uterine cervix and to document its toxicity. VBMP consisted...

Cite
Vermorken JB, Mangioni C, Pecorelli S, et al. Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. Int J Gynecol Cancer. 2000;10(5):358-365doi: 10.1046/j.1525-1438.2000.010005358.x.
Vermorken, J. B., Mangioni, C., Pecorelli, S., Van Der Burg, M. E., Van Oosterom, A. T., Ten Bokkel Huinink, W. W., Rotmensz, N., & Dalesio, O. (2000). Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 10(5), 358-365. https://doi.org/10.1046/j.1525-1438.2000.010005358.x
Vermorken, J. B., et al. "Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 10,5 (2000): 358-365. doi: https://doi.org/10.1046/j.1525-1438.2000.010005358.x
Vermorken JB, Mangioni C, Pecorelli S, Van Der Burg ME, Van Oosterom AT, Ten Bokkel Huinink WW, Rotmensz N, Dalesio O. Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. Int J Gynecol Cancer. 2000 Sep;10(5):358-365. doi: 10.1046/j.1525-1438.2000.010005358.x. PMID: 11240699.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1347 entries